AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUN 112 min read$BOLT

Bolt Biotherapeutics, Inc. (BOLT): Submission of Matters to a Vote of Security Holders

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001641281 0001641281 2025-05-27 2025-05-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

Original reporting
SEC EDGAR 8-K
Published Jun 11, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$BOLT
Neutral
high confidence
Mentioned
$BOLT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

The disclosure confirms (1) two Class II director nominees were elected and (2) PricewaterhouseCoopers LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026.

02

Market read

Routine annual meeting results; no new clinical, regulatory, or financial guidance information is provided in the text.

03

What to watch

Traders should check whether the referenced April 28, 2026 proxy (Schedule 14A) contains any substantive changes (e.g., compensation, proposals) not captured in this 8-K excerpt.

Relevance 6/10Novelty 2/10Timing: Filed June 11, 2026 after June 10 annual meeting vote results

Background

The company held its 2026 annual stockholders meeting on June 10, 2026 and reported the voting outcomes via SEC Form 8-K (Item 5.07).

Company-level read

Ticker impact

$BOLTNeutralHigh confidence
Context

Bolt Biotherapeutics filed an 8-K confirming director nominees were elected and PwC ratified as independent auditor for 2026.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted unless tied to other concurrent events not included here.

Evidence & confidence

The filing reports voting results (board election and auditor ratification) without new financial guidance, clinical/regulatory updates, or material transactions.

Market effects

Sector

Minimal; governance/auditor ratification does not change biotech sector risk factors.

Regional

Minimal; company-specific corporate action only.

Global

Minimal; no cross-border deal, regulator action, or supply-chain event described.

Counterpoint

What could challenge this read

If investors were concerned about governance/auditor continuity, the ratification could reduce perceived risk, but the article provides no evidence of such a dispute.

Key entities

  • issuer
    Bolt Biotherapeutics, Inc.

    Nasdaq-listed biotech company filing the 8-K with annual meeting voting results.

  • auditor
    PricewaterhouseCoopers LLP

    Ratified as independent registered public accounting firm for 2026.

  • executive
    William P. Quinn

    CEO/CFO signing the 8-K.

Read at source← All news

Related articles

OCT 23
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K2 min
OCT 23
$BOLTMed

Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement

Bolt Biotherapeutics (BOLT) acquired Prana Therapies via a stock-for-stock deal, exchanging shares for Prana's equity. Bolt also secured $120 million in a private placement, issuing Series D preferred stock and warrants. The funds will support operations into 2028. Prana's co-founder, Sheila Gujrathi, joined Bolt's board as chief strategy officer. BOLT shares closed at $4.19 on Nasdaq.

rttnews.com1 min
OCT 23
$BOLTHighAI 8/10

Bolt Biotherapeutics acquires Prana in reverse merger deal

Bolt Biotherapeutics (BOLT) acquired Prana Therapies in a reverse merger, raising $120M with potential for $60M more. Post-merger, Prana shareholders own 51.7% of Bolt. The combined company will advance Prana's INSPIRE platform, with Phase 2 data expected in Q2 2027. Sheila Gujrathi, Prana's co-founder, joins Bolt's board.

investing.com2 min
OCT 23
$BOLTMedAI 8/10

A $120 million financing is expected to fund Bolt's operations into 2028

Bolt Biotherapeutics (BOLT) acquired Prana Therapies, securing $120M in financing, with up to $60M more possible. The deal advances Prana's pipeline, including PRA-216, a bispecific antibody in Phase 2 trials for asthma, COPD, and atopic dermatitis. Data from all trials is expected in Q2 2027. Dr. Sheila Gujrathi, Prana's co-founder, joins Bolt's executive team. The financing is expected to fund operations into 2028.

stocktitan.net2 min